Understanding the Role of Long-Acting Injectable-Buprenorphine (LAI-B) in Community Pharmacy
Description
As part of NCAP’s REMS certification initiative for LAI-B, we invite you to join us for an educational webinar on integrating LAI-B services into the community pharmacy setting. This session will cover the Brixadi® REMS certification process, product procurement, administration techniques, and ways NCAP will support your pharmacy in expanding access to OUD treatment in your community.
Speakers
June 16th at 12:00PM
June 18th at 6:30PM
Cheryl Viracola
Director of Practice Advancement
NCAP
Mina Wolfe
Grants Coordinator
NCAP
Learning Objectives:
Describe the impact of opioid use disorder (OUD) on individuals and communities and recognize the role community pharmacies can play in expanding access to treatment.
Recognize the role of long-acting injectable buprenorphine (LAI-B) in the management of OUD.
Emphasize key administration techniques and patient counseling points for Brixadi®
Describe the requirements and processes for obtaining Brixadi® REMS certification.
Members & Non-Members: FREE
June 16th at 12:00PM and June 18th at 6:30PM
Accredited for Pharmacists and Technicians: 1.0 Hour of NC-CE
